Version history

{
  "session_id": "sess_hypdebate_SDA_2026_04_16_hyp_e_20260426_152657",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "content": "\n\n# Expert Assessment: Metabolic Reprogramming to Reverse Senescence in Neurodegeneration\n\n## Druggability: Mixed\n\nThe NAMPT→SIRT1→PGC1α axis is **partially druggable but with significant caveats**:\n\n- **NAD+ precursors (NMN, NR)**: Highly tractable—ChromaDex's Tru Niagen (NR) and multiple NMN formulations are in trials. Both have acceptable safety profiles and oral bioavailability, though CNS penetration remains uncertain.\n- **NAMPT direct activators**: Theoretically targetable as an enzyme, but no potent, selective pharmacological activators have reached clinical development. The NAD+ precursor approach essentially circumvents this bottleneck.\n- **SIRT1**: Direct activators (resveratrol-era compounds) failed due to misleading assay artifacts. No viable clinical SIRT1 activators exist—this node remains undruggable via small molecules.\n- **PGC1α**: Transcription co-activator with no direct small-molecule interface; typically targeted through upstream pathways or experimental gene therapy approaches.\n\n## Fundamental Feasibility Concerns\n\nThe core scientific premise carries **substantial risk**. \"Reversing senescence\" contradicts the operational definition of senescence as irreversible cell cycle arrest. Whether truly arrested neurons can be coaxed back to functional fidelity is unknown. Key unknowns:\n\n- **CNS delivery**: Peripheral NAD+ elevation does not reliably predict brain NAD+ levels due to blood-brain barrier"
}